fenofibrate and metyrapone

fenofibrate has been researched along with metyrapone in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Andrew, R; Homer, NZ; Karpe, F; Stimson, RH; Tan, GD; Wake, DJ; Walker, BR	1

Reviews

1 review(s) available for fenofibrate and metyrapone

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

1 trial(s) available for fenofibrate and metyrapone

Article	Year
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:5 Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Aged; Cortisone; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Fenofibrate; Gas Chromatography-Mass Spectrometry; Hormone Antagonists; Humans; Hydrocortisone; Hypolipidemic Agents; Insulin Resistance; Kinetics; Liver; Male; Metyrapone; Microdialysis; Middle Aged; Mifepristone; Obesity; PPAR alpha; PPAR gamma; Rosiglitazone; Subcutaneous Fat; Thiazolidinediones	2007

Article

Year

Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.

The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:5

Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Aged; Cortisone; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Fenofibrate; Gas Chromatography-Mass Spectrometry; Hormone Antagonists; Humans; Hydrocortisone; Hypolipidemic Agents; Insulin Resistance; Kinetics; Liver; Male; Metyrapone; Microdialysis; Middle Aged; Mifepristone; Obesity; PPAR alpha; PPAR gamma; Rosiglitazone; Subcutaneous Fat; Thiazolidinediones

2007

Other Studies

2 other study(ies) available for fenofibrate and metyrapone

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011

Article

Year

Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.

Chemical research in toxicology, 2010, Volume: 23, Issue:1

Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010

FDA-approved drug labeling for the study of drug-induced liver injury.

Drug discovery today, 2011, Volume: 16, Issue:15-16

Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011